Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Moodys
Colorcon
Dow
Harvard Business School

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR MESNEX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mesnex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002804 ↗ Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma Completed National Cancer Institute (NCI) Phase 2 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002804 ↗ Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma Completed Children's Oncology Group Phase 2 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002816 ↗ Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816 ↗ Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 1996-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002829 ↗ Bone Marrow Transplantation in Treating Patients With Lymphoma Completed National Cancer Institute (NCI) Phase 2 1994-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mesnex

Condition Name

Condition Name for Mesnex
Intervention Trials
Leukemia 14
Lymphoma 12
Sarcoma 7
Acute Lymphoblastic Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mesnex
Intervention Trials
Leukemia 28
Precursor Cell Lymphoblastic Leukemia-Lymphoma 25
Leukemia, Lymphoid 24
Lymphoma 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mesnex

Trials by Country

Trials by Country for Mesnex
Location Trials
United States 445
Canada 48
Australia 15
Poland 6
Puerto Rico 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mesnex
Location Trials
Texas 46
Illinois 20
Tennessee 20
New York 15
Pennsylvania 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mesnex

Clinical Trial Phase

Clinical Trial Phase for Mesnex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mesnex
Clinical Trial Phase Trials
Completed 33
Terminated 22
Recruiting 21
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mesnex

Sponsor Name

Sponsor Name for Mesnex
Sponsor Trials
M.D. Anderson Cancer Center 30
National Cancer Institute (NCI) 23
Children's Oncology Group 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mesnex
Sponsor Trials
Other 105
NIH 25
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
Medtronic
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.